1. Home
  2. CIVB vs DSGN Comparison

CIVB vs DSGN Comparison

Compare CIVB & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Civista Bancshares Inc.

CIVB

Civista Bancshares Inc.

HOLD

Current Price

$23.04

Market Cap

433.8M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.95

Market Cap

418.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIVB
DSGN
Founded
1884
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.8M
418.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CIVB
DSGN
Price
$23.04
$9.95
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$25.40
$13.50
AVG Volume (30 Days)
72.0K
530.3K
Earning Date
10-23-2025
11-05-2025
Dividend Yield
2.95%
N/A
EPS Growth
33.31
N/A
EPS
2.66
N/A
Revenue
$163,095,000.00
N/A
Revenue This Year
$18.06
N/A
Revenue Next Year
$11.12
N/A
P/E Ratio
$8.66
N/A
Revenue Growth
11.28
N/A
52 Week Low
$17.47
$2.60
52 Week High
$25.59
$10.29

Technical Indicators

Market Signals
Indicator
CIVB
DSGN
Relative Strength Index (RSI) 65.92 71.98
Support Level $21.10 $8.58
Resistance Level $23.44 $9.85
Average True Range (ATR) 0.50 0.66
MACD 0.09 0.13
Stochastic Oscillator 85.22 86.62

Price Performance

Historical Comparison
CIVB
DSGN

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: